Su376 METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN GENERAL POPULATION IN MEXICO: PREVALENCE, CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS.

Cervera, Luis A. Chi; Remes-Troche, José María; Reyes, Raúl Bernal; Amieva-Balmori, Mercedes; Priego-Parra, Bryan Adrián; Rodríguez, Leonardo; Vazquez, S; Méndez-Guerrero, Osvely; Chávez, Mario Andrés González

doi:10.1016/s0016-5085(21)02317-9

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another cohort study, the prevalence of MAFLD in the Veterans Affairs (VA) primary care setting was estimated to be 40%; 13.2% of these cases reported significant hepatic fibrosis (!F2) [20]. In North America, a study from Mexico that included 585 subjects from the general population suggested the prevalence of MAFLD was 41.35% [21].…”

Section: Key Pointsmentioning

confidence: 99%

Metabolic dysfunction-associated fatty liver disease: a year in review

Alharthi

Gastaldelli

Homer

et al. 2022

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of reviewIn 2020, a novel comprehensive redefinition of fatty liver disease was proposed by an international panel of experts. This review aims to explore current evidence regarding the impact of this new definition on the current understanding of the epidemiology, pathogenesis, diagnosis, and clinical trials for fatty liver disease. Recent findingsThe effectiveness of metabolic dysfunction-associated fatty liver disease (MAFLD) was compared to the existing criteria for nonalcoholic fatty liver disease (NAFLD). Recent data robustly suggest the superior utility of MAFLD in identifying patients at high risk for metabolic dysfunction, the hepatic and extra-hepatic complications, as well as those who would benefit from genetic testing, including patients with concomitant liver diseases. This change in name and criteria also appears to have improved disease awareness among patients and physicians.

show abstract

Section: Key Pointsmentioning

confidence: 99%

Metabolic dysfunction-associated fatty liver disease: a year in review

Alharthi

Gastaldelli

Homer

et al. 2022

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

show abstract

The NAFLD‐MAFLD debate: Is there a Consensus‐on‐Consensus methodology?

Fouad

Dufour²,

Zheng

et al. 2022

Liver International

View full text Add to dashboard Cite

Polarizing opinions have recently arisen in hepatology on the name and redefinition of fatty liver disease associated with metabolic dysfunction. In spite of growing and robust evidence of the superior utility of the term metabolic (dysfunction) associated fatty liver disease (MAFLD) definition for clinical and academic practice, controversy abounds. It should therefore come, as no surprise that the most common arguments used in contrarian op‐eds is that there are no consensus on any name change. In this context, we suggest that discourse on an accurate understanding of what scientific consensus means, the various methods of achieving consensus, as well as other alternative models for reaching agreement is pivotal for the field. In this opinion piece, we provide an overview of these aspects as it applies to the case of fatty liver disease. We provide evidence that consensus on a change from non‐alcoholic fatty liver disease (NAFLD) to MAFLD has already been achieved. We believe that the time has come for redirecting stakeholder focus and energy on capitalizing on the momentum generated by the debate to improve the lives of people at its centre, our patients.

show abstract

Su376 METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN GENERAL POPULATION IN MEXICO: PREVALENCE, CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS.

Cited by 2 publications

References 0 publications

Metabolic dysfunction-associated fatty liver disease: a year in review

Metabolic dysfunction-associated fatty liver disease: a year in review

The NAFLD‐MAFLD debate: Is there a Consensus‐on‐Consensus methodology?

Contact Info

Product

Resources

About